Archer Aviation (ACHR) Gets a Buy from Canaccord Genuity

In a report released today, Austin Moeller from Canaccord Genuity maintained a Buy rating on Archer Aviation (ACHR – Research Report), with a price target of $13.00. The company's shares opened today at $10.08.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Moeller is a 4-star analyst with an average return of 9.5% and a 46.19% success rate. Moeller covers the Industrials sector, focusing on stocks such as Spire Global, Archer Aviation, and Joby Aviation.
In addition to Canaccord Genuity, Archer Aviation also received a Buy from Cantor Fitzgerald's Andres Sheppard in a report issued on June 10. However, on May 29, Barclays maintained a Hold rating on Archer Aviation (NYSE: ACHR).

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

32 minutes ago

• Yahoo

Accenture (ACN) Target Price Raised by JP Morgan

Accenture plc (NYSE:ACN) is one of the 11 must-buy AI stocks analysts are betting on. On June 16, JPMorgan analyst Tien Tsin Huang reiterated an Overweight rating on the stock and increased the price target to $353 from $349. The adjustment underscores a positive outlook on the company's performance. Pixabay/Public Domain Additionally, the analyst reiterated the Overweight rating based on the expectation that Accenture would deliver better-than-expected fiscal third-quarter results. The company is expected to report revenue in line with forecasts, with a slight increase in earnings due to currency fluctuations. Accenture's fiscal 2025 revenue is expected to remain steady at its midpoint. Accenture plc (NYSE:ACN) is a global professional services company that provides a wide range of services, including strategy, consulting, digital, technology, and operations. Its solutions help clients reinvent their businesses, leveraging technology, data, AI, and new working methods. While we acknowledge the potential of ACN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Healthcare Stocks to Buy Now and 10 Stocks Analysts Are Upgrading Today. Disclosure: None.

Yahoo

33 minutes ago

• Yahoo

San Juan Basin Royalty Trust Declares No Cash Distribution for June 2025

DALLAS, June 20, 2025 /PRNewswire/ -- Argent Trust Company, as the trustee (the "Trustee") of the San Juan Basin Royalty Trust (the "Trust") (NYSE: SJT), today reported that it will not declare a monthly cash distribution to the holders of its Units of beneficial interest (the "Unit Holders") due to the application of net proceeds of $294,238, which amount would otherwise be payable to the Trust as royalty income, to the balance of excess production costs accrued as a result of Hilcorp San Juan L.P.'s ("Hilcorp") drilling of two new horizonal wells in 2024. Excess production costs occur when production costs and capital expenditures exceed the gross proceeds for a certain period. The balance of cumulative excess production costs is currently approximately $14,767,940 gross ($11,075,955 net to the Trust), a decrease in the deficit of $392,317 gross ($294,238 net to the trust) from last month's reporting period. Hilcorp will continue to charge the balance of excess production costs to the Trust's net proceeds each month. Until the balance is paid in full, the Trust will not receive royalty income as all net proceeds will be applied to the balance of excess production costs. No cash distributions will be made by the Trust until future net proceeds are sufficient to pay Trust liabilities and replenish cash reserves. Hilcorp reported $4,558,987 of total revenue from the Subject Interests for the production month of April 2025, consisting of $4,403,222 of gas revenues and $155,765 of oil revenues. For the Subject Interests, Hilcorp reported $4,201,917 of production costs (excluding the balance of excess production costs) for the production month of April 2025, consisting of $2,510,928 of lease operating expenses, $568,685 of severance taxes, and $1,122,304 of capital costs. Based upon information provided to the Trust by Hilcorp, gas volumes for the Subject Interests for April 2025 totaled 2,349,703 Mcf (2,610,782 MMBtu), as compared to 2,448,569 Mcf (2,720,632 MMBtu) for March 2025. Dividing gas revenues by production volume yielded an average gas price for April 2025 of $1.87 per Mcf ($1.69 per MMBtu), a decrease of $0.95 per Mcf ($0.85 per MMBtu) as compared to the average gas price for March 2025 of $2.82 per Mcf ($2.54 per MMBtu). This month's Trust administrative expenses totaled $135,339. The increase in administrative expenses was attributable to differences in timing of the receipt and payment of certain expenses by the Trust. Interest income received by the Trust in the amount of $394 will be applied to cover a portion of this month's Trust administrative expenses. Pursuant to the Amended and Restated Royalty Trust Indenture, dated December 12, 2007 (as amended on February 15, 2024, by the First Amendment to the Amended and Restated Royalty Trust Indenture), the Trustee is authorized to retain, in its sole discretion, a cash reserve for payment of Trust liabilities that are contingent or uncertain or otherwise not currently due and payable. To cover Trust expenses during any period of revenue shortfall, which has resulted and may continue to result from lower commodity prices and increased capital expenditures and lease operating expenses under Hilcorp's 2024 capital project plan for the Subject Interests, the Trustee increased the cash reserves in March and April of 2024, such that total cash reserves were $1.8 million as of April 30, 2024. Interest income and cash reserves were utilized to pay Trust administrative expenses each month from May 2024 through May of 2025. As of May 31, 2025, the balance of cash reserves maintained by the Trustee was $32,959. On May 21, 2025, the Trust entered into a promissory note (the "Note") to establish a line of credit (the "Line of Credit") in the amount of $2,000,000 with Texas Bank, together with a mortgage to secure that Note. The Line of Credit is intended to cover the Trust's administrative expenses until the Trust receives royalty income in amounts sufficient to (a) repay the balance of excess production costs accrued as a result of Hilcorp San Juan L.P.'s drilling of two new horizonal wells in 2024, (b) replenish a reserve in the amount of $2,000,000, and (c) repay the principal due under the Note, after which time, the Trust will resume distributions of the net profits income to the holders of the Trust's units of beneficial interest. On June 18, 2025, cash reserves in the amount of $212 were utilized to pay interest accrued on the Line of Credit, such that the balance of cash reserves maintained by the trust is $32,747. Interest income in the amount of $394, a draw of $132,851 from the Trust's Line of Credit at Texas Bank, and $1883 of cash reserves remaining from an over withdrawal of funds from the reserves in April 2025 will be used to pay Trust administrative expenses for the month of June. Production from the Subject Interests continues to be gathered, processed, and sold under market sensitive and customary agreements, as recommended for approval by the Trust's Consultant. The Trustee continues to engage with Hilcorp regarding its ongoing accounting and reporting to the Trust, and the Trust's third-party compliance auditors continue to audit payments made by Hilcorp to the Trust, inclusive of sales revenues, production costs, capital expenditures, adjustments, actualizations, and recoupments. The Trust's auditing process has also included detailed analysis of Hilcorp's pricing and rates charged. As previously disclosed in the Trust's filings, these revenues and costs (along with all costs) are the subject of the Trust's ongoing comprehensive audit process by the Trust's professional consultants and outside counsel to analyze compliance with all the underlying operative Trust agreements and evaluate potential remedies in the event there is suspected non-compliance. As of July 21, 2025, the Trust will self-publish press releases on its website, and the release will not be included in any wire distribution, which has been the normal procedure for each monthly press release through June 20, 2025. The self-publication is due to the depletion of the Trust's cash reserves and conservation of the line of credit resources. The trust will self-publish press releases until such time as the cash reserves have been replenished and increased to $2.0 million. The Trust will continue to furnish unitholders with information through its website and Form 8-K filings with the Securities and Exchange Commission, which are available at Forward Looking Statements. Except for historical information contained in this news release, the statements in this news release are forward-looking statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements generally are accompanied by words such as "estimates," "anticipates," "could," "plan," or other words that convey the uncertainty of future events or outcomes. Forward-looking statements and the business prospects of San Juan Basin Royalty Trust are subject to a number of risks and uncertainties that may cause actual results in future periods to differ materially from the forward-looking statements. These risks and uncertainties include, among other things, certain information provided to the Trust by Hilcorp, volatility of oil and gas prices, governmental regulation or action, litigation, and uncertainties about estimates of reserves. These and other risks are described in the Trust's reports and other filings with the Securities and Exchange Commission. Contact: San Juan Basin Royalty Trust Argent Trust Company, Trustee Nancy Willis, Director of Royalty Trust Services Toll-free: (855) 588-7839 Fax: (214) 559-7010 Website: Email: trustee@ View original content: SOURCE San Juan Basin Royalty Trust Inicia sesión para acceder a tu portafolio

Yahoo

44 minutes ago

• Yahoo

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

Clareon PanOptix Pro has half the light scatter of Clareon PanOptix1-3,*,** PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics1-4,*,**,† Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,††,‡ TORONTO, June 20, 2025--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics.1-4,*,**,† These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate.1,††,‡ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix.10-13,§,§§,¶,¶¶ "As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D," said Rob Scott, VP, Intraocular Devices, R&D, Alcon. "Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro.1,3,10.14-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL."1-3,20,21,*,**,‡‡,‖,Ω "PanOptix has been a cornerstone of my cataract practice for eight years," said Dr. Rosa Braga-Mele, MD, MEd, FRCSC, Professor of Ophthalmology, University of Toronto. "These lenses have consistently delivered outstanding visual outcomes for my patients 10, 24, § – a low visual disturbance profile25, ∂and a happy patient with greater spectacle independence.23, § So, it's exciting to see this technology evolve to further meet patients' visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter is possible‡,‡‡, empowering both my practice and my patients." PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe® preloaded delivery system and as well as with the Clareon Monarch® IV delivery system in early 2026.22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering.22 For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative. About Clareon PanOptix Pro The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the Directions for Use regarding indications, precautions, cautions and warnings which is available at About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at *PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light). **Based on manufacturer-reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner. †For feasible diffractive optics of up to pentafocal design from Krackhardt et al. ††Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic. ‡Compared to Clareon PanOptix. ‡‡Based on bench and vision simulator studies. §Based on prospective multicenter randomized study at 6 months, significantly more subjects reported not experiencing starburst and glare (p<0.05 n=276). §§All-implanted analysis set. ¶In response to the IOLSAT questionnaire question "In the past 7 days, how often did you need to wear eyeglasses to see"? ¶¶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127. ‖Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof IQ PanOptix through Q1, 2024. ΩSeverity ratings by phakic patients with simulated implant of Clareon PanOptix Pro and Clareon PanOptix using VirtIOL simulator (n=64). ∂Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including "very bothersome" and "severe" visual disturbances. Clinical studies were performed on the AcrySof IQ PanOptix IOL; AcrySof IQ PanOptix and Clareon PanOptix are optically equivalent. References Alcon data on file, 2025. REF-25218 Alcon data on file, 2024. REF-25221 Alcon data on file, 2015. REF-08546 Krackhardt U, et al: Upper bound on the diffraction efficiency of phase-only fanout elements. Applied Optics; 1992; 31:27-37.; 10. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston. Rayner Professional Website. Accessed September 2024. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; Accessed September 2024. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234. Alcon data on file, 2024. REF-23958. Alcon data on file, 2018. REF-01475. Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965 Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164 Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/ Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/ Alcon data on file, 2024. REF-25903 Alcon data on file, 2024. REF-23554 MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023. Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use. Zhu D, et al. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/ Vision LLC. Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. Ophthalmology. 2021;128(2):197-207. doi:10.1016/ Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. Connect with us onFacebook LinkedIn View source version on Contacts Media Relations Jane Lee Cheung+1 289 290 2393 (Canada) Sign in to access your portfolio